Despite statin‐controlled LDL‐C levels, CV events were greater among patients with diabetes and high TG levels. Because we controlled for cardiometabolic risk factors, it is likely that the difference in TG levels contributed to the excess risk observed in patients with high TGs (Diabetes, Obesity and Metabolism)
Diabetes News
Category: Cardiovascular
Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study
The development of T2D in an incident population of PsA is significantly higher than in psoriasis alone or in a general population, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar (Rheumatology)
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk
This study suggests a paradoxical association of BMI with cardiovascular and mortality risks in different ethnic groups, which may partially be driven by different cardiovascular and glycaemic risk profiles at diagnosis (Acta Diabetologica)
The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices
This study shows that in patients with T2D on insulin therapy, increased urinary ACR is independently associated with an increased risk of major adverse CV events and all-cause mortality (Nephrology Dialysis Transplantation)
Cardiovascular Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients with Type 2 Diabetes
Using population‐based data, incident use of SGLT‐2 inhibitors was associated with a decreased incidence of CVD compared to sulfonylurea and DPP‐4 inhibitors. These findings were consistent between dapagliflozin and canagliflozin suggesting that CVD reduction is a class effect for SGLT2 inhibitors (Diabetes, Obesity and Metabolism)
Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary
The risk of cardiovascular outcomes and all-cause mortality is significantly higher in patients with T2DM. Notably, the relative hazard increases with decreasing age suggesting that younger patients with T2DM should receive more attention for cardiovascular prevention (Cardiovascular Diabetology)
Impact of acute diabetes decompensation on outcomes of diabetic patients admitted with ST-elevation myocardial infarction
Decompensated diabetes complicates ~ 1.5% of STEMI admissions in diabetic patients. It is associated with lower rates of referral for angiography and revascularization, and a negative differential impact on in-hospital morbidity and mortality and cost (Diabetology & Metabolic Syndrome)
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus
Our findings suggest that SGLT-2i reduced hHF compared with DPP-4i. A heart failure protective effect of SGLT-2i use vs. DPP-4i use was shown 30 days after initiating the SGLT-2i among patients with established CVD, but this effect appeared later in patients without established CVD (Cardiovascular Diabetology)
SGLT-2 Inhibitors and Cardiovascular Risk
In this large, multinational, observational study, initiation of SGLT-2i was associated with lower risk of death and HF regardless of pre-existing CVD. Ongoing clinical trials will provide further evidence regarding the benefit of SGLT-2i in patients without established CVD (Journal of the American College of Cardiology)
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
The beneficial effects of SGLT2 inhibitors on such outcomes and the heart itself are unique characteristics among antidiabetic agents, and SGLT2 inhibitors are expected to be a promising therapeutic option for CV disease and HF care (Cardiovascular Diabetology)
Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year
A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after 1 year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased (Cardiovascular Diabetology)
Bone markers and cardiovascular risk in type 2 diabetes patients
Higher osteopontin concentrations were associated with an increased CVD risk in type 2 diabetes patients. No consistent associations were found for the other five bone markers and risk of CVD in type 2 diabetes patients (Cardiovascular Diabetology)
Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function
Exercise capacity is reduced in T2DM subjects relative to matched controls, whereas exercise capacity is preserved in T1DM. There was no evidence of sub-clinical cardiac dysfunction but, rather, there was an association between impaired exercise capacity, small LV volumes and sedentary behavior (Cardiovascular Diabetology)
Myocardial Infarction Subtypes in Patients with Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (From the LEADER Trial)
This analysis showed that liraglutide reduces the incidence of MIs in patients with type 2 DM at high CV risk, and may impact the clinical outcomes of MI (American Journal of Cardiology)
Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates
Our data support that short-term multifactorial treatment of patients with glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and associated with a clinically meaningful improvement in CVD risk (BMJ)
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
The 3rd CVOT Summit of the D&CVD EASD Study Group discussed key results of recent CVOTs and new studies on lipid-lowering strategies in an interactive multi-disciplinary format. The summit discussed both potentials and limitations of current CVOT designs as well as strategies for the implementation of CVOT results in treatment guidelines. It also discussed potential elements for future design of CVOTs in diabetes and shaped the role for real-world data (Cardiovascular Diabetology)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns (The Lancet Diabetes & Endocrinology)
Trends in cardiovascular risk factor management in type 1 diabetes by sex
Although the adoption of intensive insulin therapy and obtaining ADA HbA1c recommendations are increasing, overall cardiovascular risk factor compliance remains low and merits further intervention (Journal of Diabetes and Its Complications)
Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes
Physicians should not be falsely reassured by claims that a new treatment appears to have passed a narrowly-defined regulatory test. The management of diabetic patients often carries with it the risk of important cardiovascular consequences, even for drugs that do not overtly increase the risk of myocardial infarction or stroke (Diabetes, Obesity and Metabolism)
Cardiac Autonomic Neuropathy: Why Should Cardiologists Care about That?
Because diabetes mellitus often coexists with heart diseases and the most common methods used for diagnosis of Cardiac autonomic neuropathy (CAN) are based on ECG, not only diabetologists but also cardiologists should be responsible for diagnosis of CAN (Journal of Diabetes Research)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »
Glycosmedia is also available as an App: